Vivaxim Drug Interactions

VIVAXIM must not be mixed with other vaccines in the same syringe.
Concomitant administration of VIVAXIM with the combined, adsorbed, tetanus, low dose diphtheria and inactivated poliomyelitis vaccine (Td-IPV) at two separate sites demonstrated non-inferiority compared to the separate administration of the two vaccines at different time points for all valences, except for the Vi valence, in terms of immune response obtained one month after vaccination. Nevertheless, anti-Vi seroconversion rate (≥ 4-fold rise) for concomitant administration was non-inferior to the separate administration in subjects who were not seroprotected before vaccination (see Pharmacology: Pharmacodynamics under Actions). Since the seroprotection rate (the percentage of subjects reaching the threshold of protection for anti-Vi antibodies ≥1 μg/mL) was consistent with the expected rate of responses when VIVAXIM is given alone, it is unlikely that concomitant administration of VIVAXIM with the Td-IPV at different sites will have clinical consequences. Therefore, concomitant administration of VIVAXIM with the Td-IPV at two separate sites can be performed.
No interaction studies have been performed with VIVAXIM and other inactivated vaccines. However, based on data obtained from the concomitant administration of the monovalent typhoid Vi polysaccharide vaccine with diphtheria-tetanus (DT), tetanus-inactivated poliomyelitis (T-IPV), rabies, meningococcal polysaccharide A/C vaccines, no interferences with the immune responses to any of these antigens are expected.
Concomitant administration of yellow fever vaccine and VIVAXIM has not been specifically studied. However, based on data obtained from the concomitant administration of the monovalent vaccines (purified Vi polysaccharide typhoid vaccine and inactivated Hepatitis A vaccine) with yellow fever vaccine show that no interference between the immune response to these three antigens is expected.
The effect of the concomitant administration of immunoglobulins on the immunogenicity of VIVAXIM has not been assessed. Therefore, interference with the immune response to VIVAXIM cannot be ruled out.
Data obtained during concomitant administration of immunoglobulins with the monovalent inactivated hepatitis A vaccine showed that anti-HAV seroconversion rates were not modified whereas anti-HAV antibody titres could be lower than after vaccination with a monovalent vaccine alone.